Skip to content

BridgeBio Pharma

US · BBIO #1254 by market cap Listed 2019
76.03 -2.15 -2.75%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Recent news

  • Rating change
    CCORF Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $106
    Market Newswire · 2026/10/7
  • Morgan Stanley Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $91
    Market Newswire · 2026/11/13
  • Rating change
    Wells Fargo Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $102
    Market Newswire · 2026/10/15
  • Rating change
    H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $120
    Market Newswire · 2026/10/16
  • CCORF Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $108
    Market Newswire · 2026/11/2
  • Rating change
    RBC Capital Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/10/9
  • Rating change
    Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $91
    Market Newswire · 2026/10/21
  • Rating change
    UBS Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $92
    Market Newswire · 2026/10/15
  • Rating change
    Morgan Stanley Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $87
    Market Newswire · 2026/10/21
  • Rating change
    A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $88 to $130
    Market Newswire · 2026/10/31
  • Rating change
    Cantor Fitzgerald Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/10/26
  • Rating change
    Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $120
    Market Newswire · 2026/10/19
  • Rating change
    BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $102
    Market Newswire · 2026/10/19
  • Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $156
    Market Newswire · 2026/11/2
  • Rating change
    A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $91 to $120
    Market Newswire · 2026/10/30
  • Rating change
    Morgan Stanley Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $87
    Market Newswire · 2026/10/22
  • Rating change
    Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Cuts Target Price to $91
    Market Newswire · 2026/10/19
  • Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $120
    Market Newswire · 2026/11/20
  • BridgeBio Pharma(BBIO.US) Officer Sells US$4.28 Million in Common Stock
    Market Newswire · 2026/11/21
  • Rating change
    UBS Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $92
    Market Newswire · 2026/10/15
  • Rating change
    A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $104 to $156
    Market Newswire · 2026/10/7
  • Rating change
    Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157
    Market Newswire · 2026/9/30
  • Earnings Flash (BBIO) BridgeBio Pharma Posts Q3 Per-Share Loss $0.42, Vs. FactSet Est of $0.54 Loss
    MT Newswires · 2026/10/30
  • Rating change
    Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $115
    Market Newswire · 2026/8/31
  • Rating change
    TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/9/24

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:01:24 · For reference only, not investment advice and not tailored to your situation.

BridgeBio Pharma discussion 0 comments

Add a comment